Physician profile
Thomas B Raper
NPI 1417995044
$4,856.89
in general payments reported to CMS, 2019-2025
29 companies · $901 in 2025
The $901 reported for 2025 was more than what 76% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,123 · 2021: $130 · 2022: $229 · 2023: $398 · 2024: $1,019 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264 · Education: $53.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.91 |
| Education | $53.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $1,000.00 | 2020 | |
| Glaxosmithkline, LLC. | $825.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $448.28 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Inari Medical, INC. | $353.02 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $290.78 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.16 | 2019-2025 | Ofev, Jascayd |
| Aop Health US, LLC | $214.69 | 2025 | Rapiblyk |
| Inspire Medical Systems, INC. | $159.06 | 2024-2025 | Inspire |
| Insmed, INC. | $147.78 | 2019-2025 | Arikayce, Brinsupri |
| Abiomed | $144.74 | 2023 | Impella |
| Pulmonx Corporation | $137.12 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Mylan Specialty L.P. | $115.63 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $113.69 | 2019 | |
| Philips North America LLC | $93.63 | 2019-2024 | (Ak6) Vest Therapy |
| Grifols USA, LLC | $87.32 | 2019-2025 | Prolastin-C Liquid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $75.81 | 2022-2024 | Zerbaxa, Recarbrio |
| Jazz Pharmaceuticals INC. | $59.20 | 2024 | |
| Resmed Corp | $53.96 | 2024 | |
| Itamar Medical INC | $40.87 | 2022-2023 | Watchpatone |
| Mallinckrodt Enterprises LLC | $39.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.13 | 2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $31.25 | 2021 | |
| Abbvie INC. | $23.80 | 2024 | |
| Electromed, INC. | $23.33 | 2021 | |
| Amgen INC. | $19.09 | 2025 | Tezspire |
| Mayne Pharma Commercial LLC | $18.81 | 2020 | |
| Verona Pharma, INC. | $15.94 | 2025 | Ohtuvayre |
| Shire North American Group INC | $15.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.56 | 2025 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Raper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.